Chemotherapy with adriamycin and vincristine alternated with cyclophosphamide and actinomycin D in testicular germ cell tumors refractory to cisplatin, vinblastine and bleomycin

S. Crispino, G. Pizzocaro, S. Marchini, S. Monfardini

Research output: Contribution to journalArticle

Abstract

Eighteen patients with testicular cancer refractory to cisplatin, vinblastine and bleomycin (PVB) were treated with a non-cross-resistant regimen including adriamycin, 60 mg/m2 i.v. on day 1, and vincristine, 1.2 mg/m2 i.v. on days 1 and 8, alternated q 3 weeks with cyclophosphamide, 600 mg/m2 i.v. on days 1 and 8, and actinomycin D, 1 mg/m2 i.v. on days 1 and 8. The median number of administered cycles was 8 (range 3-14). The results were analyzed according to previous response to PVB. One of two patients relapsing after the first-line therapy obtained a transient second complete response (CR) (duration 7 months). None of seven patients who showed no response to PVB obtained a CR; in 3 9 patients with a partial response (PR) after PVB, the achievement of CR could not be definitely attributed to salvage therapy. Toxicity was mild; no cardiac failure or drug-related deaths were observed. In conclusion, these two alternating regimens were well tolerated, but this treatment was not found to be useful in patients not responsive to PVB, for whom new and alternative therapies are required. The favorable impact on prognosis, evident only in the subgroup of patients with PR, was probably attributable to PVB rather than to this salvage regimen.

Original languageEnglish
Pages (from-to)251-256
Number of pages6
JournalEuropean Journal of Cancer and Clinical Oncology
Volume22
Issue number3
DOIs
Publication statusPublished - 1986

Fingerprint

Vinblastine
Bleomycin
Dactinomycin
Vincristine
Doxorubicin
Cyclophosphamide
Cisplatin
Drug Therapy
Salvage Therapy
Testicular Neoplasms
Complementary Therapies
Testicular Germ Cell Tumor
Heart Failure
Therapeutics
Pharmaceutical Preparations

ASJC Scopus subject areas

  • Oncology

Cite this

Chemotherapy with adriamycin and vincristine alternated with cyclophosphamide and actinomycin D in testicular germ cell tumors refractory to cisplatin, vinblastine and bleomycin. / Crispino, S.; Pizzocaro, G.; Marchini, S.; Monfardini, S.

In: European Journal of Cancer and Clinical Oncology, Vol. 22, No. 3, 1986, p. 251-256.

Research output: Contribution to journalArticle

@article{cabd0e5038cc45678ae226e167d880f2,
title = "Chemotherapy with adriamycin and vincristine alternated with cyclophosphamide and actinomycin D in testicular germ cell tumors refractory to cisplatin, vinblastine and bleomycin",
abstract = "Eighteen patients with testicular cancer refractory to cisplatin, vinblastine and bleomycin (PVB) were treated with a non-cross-resistant regimen including adriamycin, 60 mg/m2 i.v. on day 1, and vincristine, 1.2 mg/m2 i.v. on days 1 and 8, alternated q 3 weeks with cyclophosphamide, 600 mg/m2 i.v. on days 1 and 8, and actinomycin D, 1 mg/m2 i.v. on days 1 and 8. The median number of administered cycles was 8 (range 3-14). The results were analyzed according to previous response to PVB. One of two patients relapsing after the first-line therapy obtained a transient second complete response (CR) (duration 7 months). None of seven patients who showed no response to PVB obtained a CR; in 3 9 patients with a partial response (PR) after PVB, the achievement of CR could not be definitely attributed to salvage therapy. Toxicity was mild; no cardiac failure or drug-related deaths were observed. In conclusion, these two alternating regimens were well tolerated, but this treatment was not found to be useful in patients not responsive to PVB, for whom new and alternative therapies are required. The favorable impact on prognosis, evident only in the subgroup of patients with PR, was probably attributable to PVB rather than to this salvage regimen.",
author = "S. Crispino and G. Pizzocaro and S. Marchini and S. Monfardini",
year = "1986",
doi = "10.1016/0277-5379(86)90388-3",
language = "English",
volume = "22",
pages = "251--256",
journal = "European Journal of Cancer",
issn = "0959-8049",
publisher = "Elsevier Ltd",
number = "3",

}

TY - JOUR

T1 - Chemotherapy with adriamycin and vincristine alternated with cyclophosphamide and actinomycin D in testicular germ cell tumors refractory to cisplatin, vinblastine and bleomycin

AU - Crispino, S.

AU - Pizzocaro, G.

AU - Marchini, S.

AU - Monfardini, S.

PY - 1986

Y1 - 1986

N2 - Eighteen patients with testicular cancer refractory to cisplatin, vinblastine and bleomycin (PVB) were treated with a non-cross-resistant regimen including adriamycin, 60 mg/m2 i.v. on day 1, and vincristine, 1.2 mg/m2 i.v. on days 1 and 8, alternated q 3 weeks with cyclophosphamide, 600 mg/m2 i.v. on days 1 and 8, and actinomycin D, 1 mg/m2 i.v. on days 1 and 8. The median number of administered cycles was 8 (range 3-14). The results were analyzed according to previous response to PVB. One of two patients relapsing after the first-line therapy obtained a transient second complete response (CR) (duration 7 months). None of seven patients who showed no response to PVB obtained a CR; in 3 9 patients with a partial response (PR) after PVB, the achievement of CR could not be definitely attributed to salvage therapy. Toxicity was mild; no cardiac failure or drug-related deaths were observed. In conclusion, these two alternating regimens were well tolerated, but this treatment was not found to be useful in patients not responsive to PVB, for whom new and alternative therapies are required. The favorable impact on prognosis, evident only in the subgroup of patients with PR, was probably attributable to PVB rather than to this salvage regimen.

AB - Eighteen patients with testicular cancer refractory to cisplatin, vinblastine and bleomycin (PVB) were treated with a non-cross-resistant regimen including adriamycin, 60 mg/m2 i.v. on day 1, and vincristine, 1.2 mg/m2 i.v. on days 1 and 8, alternated q 3 weeks with cyclophosphamide, 600 mg/m2 i.v. on days 1 and 8, and actinomycin D, 1 mg/m2 i.v. on days 1 and 8. The median number of administered cycles was 8 (range 3-14). The results were analyzed according to previous response to PVB. One of two patients relapsing after the first-line therapy obtained a transient second complete response (CR) (duration 7 months). None of seven patients who showed no response to PVB obtained a CR; in 3 9 patients with a partial response (PR) after PVB, the achievement of CR could not be definitely attributed to salvage therapy. Toxicity was mild; no cardiac failure or drug-related deaths were observed. In conclusion, these two alternating regimens were well tolerated, but this treatment was not found to be useful in patients not responsive to PVB, for whom new and alternative therapies are required. The favorable impact on prognosis, evident only in the subgroup of patients with PR, was probably attributable to PVB rather than to this salvage regimen.

UR - http://www.scopus.com/inward/record.url?scp=0022620982&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0022620982&partnerID=8YFLogxK

U2 - 10.1016/0277-5379(86)90388-3

DO - 10.1016/0277-5379(86)90388-3

M3 - Article

VL - 22

SP - 251

EP - 256

JO - European Journal of Cancer

JF - European Journal of Cancer

SN - 0959-8049

IS - 3

ER -